Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent

Coronavirus disease outbreak caused a severe public health burden all over the world. Salinomycin (SAL) is a broad-spectrum antibiotic that had drawn attention in selective targeting of cancer and viral infections. Recent drug screen identified SAL as a potent antiviral agent against SARS-CoV-2. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Pindiprolu, Sai Kiran S.S., Kumar, Chirravuri S. Phani, Kumar Golla, Venu Sampath, P., Likitha, K., Shreyas Chandra, S.K., Esub Basha, R.K., Ramachandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260485/
https://www.ncbi.nlm.nih.gov/pubmed/32516655
http://dx.doi.org/10.1016/j.mehy.2020.109858
Descripción
Sumario:Coronavirus disease outbreak caused a severe public health burden all over the world. Salinomycin (SAL) is a broad-spectrum antibiotic that had drawn attention in selective targeting of cancer and viral infections. Recent drug screen identified SAL as a potent antiviral agent against SARS-CoV-2. In this hypothesis, we discuss the potential of pulmonary delivery of SAL using nanostructured lipid carriers (NLCs) against SARS-CoV-2.

Ejemplares similares